The effective blockade of IL-1β and the inhibition of NLRP3 inflammasome to block IL-1β and IL-18 response are the ongoing therapeutic targets for the treatment of RA [5, 81, 82]. This evidence concerns the gene NLRP3 and rheumatoid arthritis.